STEM

[Cadavre Exquis]

Figure · 2026.03.09 · Helix 02 Living Room Tidy

Saludos.

[Cadavre Exquis]

Linux Maintainer Greg Kroah-Hartman Says AI Tools Now Useful, Finding Real Bugs
Posted by EditorDavid on Saturday March 28, 2026 @02:34PM from the better-bugs dept.

Linux kernel maintainer Greg Kroah-Hartman tells The Register that AI-driven code review has "really jumped" for Linux. "There must have been some inflection point somewhere with the tools..."

"Something happened a month ago, and the world switched. Now we have real reports." It's not just Linux, he continued. "All open source projects have real reports that are made with AI, but they're good, and they're real." Security teams across major open source projects talk informally and frequently, he noted, and everyone is seeing the same shift. "All open source security teams are hitting this right now...."

For now, AI is showing up more as a reviewer and assistant than as a full author of Linux kernel code, but that line is starting to blur. Kroah-Hartman has already done his own experiments with AI-generated patches. "I did a really stupid prompt," he recounted. "I said, 'Give me this,' and it spit out 60: 'Here's 60 problems I found, and here's the fixes for them.' About one-third were wrong, but they still pointed out a relatively real problem, and two-thirds of the patches were right." Mind you, those working patches still needed human cleanup, better changelogs, and integration work, but they were far from useless. "The tools are good," he said. "We can't ignore this stuff. It's coming up, and it's getting better...." [H]e said that for "simple little error conditions, properly detecting error conditions," AI could already generate dozens of usable patches today.

The sudden increase in AI-generated reports and AI-assisted work has also spurred a parallel push to build AI into the kernel's own review infrastructure. A key piece of that is Sashiko, a tool originally developed at Google and now donated to the Linux Foundation.

Kroah-Hartman said some patches are being generated with AI now. "You have a little co-develop tag for that now. We're seeing some things for some new features, but we're seeing AI mostly being used in the review."

Saludos.

[Cadavre Exquis]

Pancreatic Cancer mRNA Vaccine Shows Lasting Results In Early Trial
Posted by EditorDavid on Sunday April 19, 2026 @02:34PM from the give-it-your-best-shot dept.

NBC News reports on a 16-person clinical trial of "personalized messenger RNA vaccines" which use the immune system to fight cancer cells. "The goal is not to eliminate existing tumors, but instead to stamp out lingering, undetected cancer cells, and later any new cells that form before they can cause a recurrence."

Patients still have surgery to remove tumors. After that, the mRNA vaccines are personalized for each individual using genetic material taken from their unique tumor cells. In the clinical trial, after getting the vaccine, the patients also received chemotherapy, which is standard post-op treatment for operable pancreatic cancer... [The article notes that less than 13% of people diagnosed with pancreatic cancer live for more than five years, making it "one of the deadliest cancers."]

[E]xperts have long believed that people with pancreatic cancer could not generate an immune response against tumors. But after nine doses of the personalized vaccine, [clinical trial participant Donna] Gustafson is one of eight people in the 16-person Phase 1 trial who did just that, producing an army of immune cells called T cells that seek out and destroy tumor cells... [Dr. Vinod Balachandran, a vaccine center director who is leading the trial, said] it was unclear whether the immune response would last and lead to the patients living longer... New data collected during the trial's six-year follow-up period shows that it may. Those findings will be presented Monday at the American Association for Cancer Research's annual meeting in San Diego. Six years after treatment, Gustafson and six others who responded to the treatment are still alive...

More research is still needed. Genentech and BioNTech, the two drugmakers behind the vaccine, have already launched a larger Phase 2 clinical trial... Another team is working on an off-the-shelf vaccine that targets a protein called KRAS that is present in as many as 90% of pancreatic cancers. In a small, early trial, about 85% of the participants mounted an immune response to the protein.

Saludos.

[Cadavre Exquis]

FDA Gives Green Light To the First Gene Therapy For Deafness
Posted by BeauHD on Saturday April 25, 2026 @03:00AM from the first-of-its-kind dept.

An anonymous reader quotes a report from NPR:

The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf. The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as a milestone in the quest to treat hearing loss. "It's the first time in history there's a new drug for hearing loss," says Zheng-Yi Chen, an associate scientist at Mass Eye and Ear in Boston who was not involved in the development of the therapy approved by the FDA Thursday. But his research team reported very promising results with a similar approach Wednesday. "I think it's an historical event, a landmark, a great development for the whole field," he says of the approval. [...] The FDA's decision was based on the results from the treatment of 20 patients born with a defective version of a gene known as OTOF, which is necessary to transmit sound from the ears to the brain.

Doctors infused billions of adeno-associated viruses into the patients' ears by making a small incision behind the ear to open a small hole in the skull. The viruses carried a healthy version of the OTOF gene that had been split in half to fit inside the virus. The gene provides instructions to make the otoferlin protein, which is necessary for hair cells in the inner ear to transmit sound to the brain. Most of the patients began to hear for the first time within weeks, with the quality of their hearing improving over the following months, according to [Regeneron Pharmaceuticals, which developed the gene therapy and plans to offer it for free in the U.S. It should be available within weeks.]. The amount of hearing patients gained varied, but 80% achieved at least some significant hearing restoration and 42% ended up with normal hearing, which included the ability to hear whispers, Regeneron says. The hearing ability has lasted at least two years so far.

The treatment can only help patients with the very rare form of deafness that Smith was born with, which only affects about 50 children each year in the U.S. But similar gene therapies are showing promise for other forms of genetic deafness. And researchers hope someday gene therapy may help with common types of hearing loss, like from aging and loud noise.

Saludos.